Picard Medical, Inc. (PMI) - 10-Q Summary
Business Context and Reporting Period
Company: Picard Medical, Inc. (PMI), a holding company owning SynCardia Systems, LLC. The company designs, manufactures, and sells the SynCardia Total Artificial Heart (TAH), an FDA-approved implantable system for patients with advanced heart failure.
Reporting Period: Quarterly report for the period ended June 30, 2025 (Q2 2025).
Status: Smaller reporting company and emerging growth company. The filing includes a "Going Concern" warning, noting substantial doubt about the ability to continue operations without additional financing, though a subsequent IPO in September 2025 has since addressed liquidity.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Amount (in thousands) |
|---|---|
| Total Revenues | $2,744 |
| Cost of Revenues | $3,229 |
| Gross Profit (Loss) | $(485) |
| Operating Loss | $(6,767) |
| Net Loss | $(12,285) |
| Net Loss Attributable to Common Stockholders | $(13,861) |
| Cash and Cash Equivalents (End of Period) | $410 |
| Total Current Liabilities | $45,636 |
| Convertible Notes Payable (Net) | $14,752 |
| Derivative Liability | $13,711 |
Material Changes vs. Prior Period
- Revenue: Increased 3% ($70k) compared to the six months ended June 30, 2024. Product revenue rose slightly, while rental revenue dropped to zero.
- Gross Margin: Deteriorated significantly. The company moved from a gross profit of $425k in the prior year period to a gross loss of $(485k). Cost of revenues increased 44% to $3.229M, driven by increased product manufacturing costs and rental maintenance costs.
- Net Loss: Doubled to $(12.3M) from $(6.0M) in the prior year period. This was primarily driven by a $5.2M increase in "Other Expenses," specifically non-cash derivative losses ($2.5M) and interest expense ($3.0M) related to convertible notes.
- Liquidity: Cash on hand increased from $96k to $410k, funded by financing activities ($5.1M net inflow) including convertible notes and common stock issuances, offset by operating cash outflows of $4.8M.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management explicitly stated substantial doubt about the company's ability to continue as a going concern for 12 months from the report date due to recurring losses and negative cash flows. The financial statements do not include adjustments that might be necessary if the company cannot continue.
- Subsequent Events (Post-June 30, 2025):
- IPO Completion: On September 2, 2025, the company completed an IPO raising $17.0M gross proceeds ($11.2M net). This resolved the immediate liquidity crisis.
- Debt Conversion: Convertible notes were automatically converted into common stock upon the IPO.
- Preferred Stock Conversion: Series A-1 Preferred Stock was converted to common stock in July 2025.
- Unusual Items: Significant non-cash charges included a $2.5M derivative loss and $2.4M amortization of debt discounts. These items heavily impacted the net loss but did not affect cash flow.
- Internal Controls: The company identified material weaknesses in internal controls, including lack of segregation of duties and lack of formal review processes.
Investor Verification Checklist
- Post-IPO Liquidity: Verify the actual cash balance and burn rate following the September 2025 IPO to confirm the "Going Concern" warning has been resolved.
- Debt Obligations: Confirm the full conversion of the $14.7M in convertible notes and the $13.7M derivative liability into equity, and check for any remaining debt covenants.
- Gross Margin Sustainability: Investigate the drivers of the negative gross margin (118% cost of revenue). Determine if the high rental maintenance costs are structural or temporary.
- Customer Concentration: Review the reliance on top customers (Customer A represented 39% of revenue in the six-month period) and the impact of any single customer loss.
- Internal Control Remediation: Assess the progress of the remediation plan for material weaknesses in financial reporting controls.